Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON22289
NL-OMON22289
Completed
Not Applicable

Investigating the immune response to COVID-19 vaccination in lung transplantation patients (COVALENT study)

niversity Medical Center Groningen (UMCG)0 sites180 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity Medical Center Groningen (UMCG)
Enrollment
180
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
niversity Medical Center Groningen (UMCG)

Eligibility Criteria

Inclusion Criteria

  • •? All patients should be eligible for COVID\-19 vaccination as described by the instructions of the manufacturer.
  • •? Provision of written informed consent
  • •? \=18 years of age
  • •? Belong to one of the four populations as named in 4\.1\.

Exclusion Criteria

  • •? Contra\-indications for vaccination (unrelated to the study)
  • •\-History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the study intervention(s).
  • •\-Pregnancy at the time of the vaccinations
  • •? Exclusion specific to this investigation
  • •\-No administration of SARS\-CoV\-2 vaccine due to any reason
  • •\-Active (hematological) malignancy
  • •\-Inherited immune deficiency
  • •\-Receiving anti\-retroviral medication o Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • •\-Waitlist patients with a passed COVID\-19 infection.
  • •\-Transplantation candidates who do not receive a transplantation within 15 months after receiving the second vaccination dose will remain included as controls. However, sampling will not continue after long

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Evaluation of the immune response against COVID-19 in pediatric Cancer patients after vaccinatioeed for vaccination against COVID-19C91C92Lymphoid leukaemiaMyeloid leukaemia
DRKS00025254Pädiatrische Hämatologie und OnkologieKlinik für Kinder- und JugendmedizinJohann Wolfgang Goethe Universität100
Recruiting
Not Applicable
Immune response and therapy assessment to COVID-19 Vaccinations in people with Diabetes Mellitus – an observational pilot studyE10E11Type 1 diabetes mellitusType 2 diabetes mellitus
DRKS00024879Division Exercise Physiology and Metabolism60
Recruiting
Not Applicable
Study of immunologic response after COVID-19 vaccination in kidney transplant recipientsImmune response after COVID-19 vaccination in immunosuppressed patientsCovid-19vaccinekidney transplantimmunosuppression
TCTR20210611006Ratchadapiseksompotch Fund60
Not yet recruiting
Not Applicable
COVID-19 vaccination of vulnerable populations (COVULPOP)COVID-19 vaccine responseCOVID-19Inflammatory and Immune System - Normal development and function of the immune systemRespiratory - Other respiratory disorders / diseasesInfection - Other infectious diseases
ACTRN12621001492842Prof Katie Flanagan40
Active, not recruiting
Phase 1
Humoral (antibodies) and cellular (white blood cells) immune response to COVID-19 vaccines in immunocompromised (people with impaired immune system) and healthy individuals – The CoVVac studyActive immunisation to prevent COVID-19 in immunocompromised individuals.MedDRA version: 23.1Level: PTClassification code 10084457Term: COVID-19 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Health Care [N] - Population Characteristics [N01]
EUCTR2021-001040-10-ATMedical University of Graz390